Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
During a season of giving, investors were extra generous to these biotech companies this week.
A member of BioSpace’s Class of 2021, CODA aims to modify neuronal cell populations using gene therapy to express a tunable ligand-gated ion channel.
The JP Morgan Health Care Conference is held annually in January, and usually kicks off the biggest biopharma business news stories of the year. But in 2022, it’ll do so without at least three big names in the industry.
Good data management means developing a systematic way to integrate and update data enterprise-wide and to share it with team members or partners as needed.
Bristol Myers Squibb is dropping $920 million to acquire the exclusive global rights of Immatics’ experimental cancer drug program, the companies announced Tuesday morning.
Texas’ top law enforcement official is taking aim at two drug companies over what he alleges is the promotion of hormone blockers for children experiencing gender dysphoria.
AnHeart Therapeutics raised $61 million in a Series B financing round. Proceeds from the round will be used for the company’s lead asset, a next-generation ROS1 inhibitor currently in Phase II trials in non-small cell lung cancer.
The FDA said that it is not authorizing molnupiravir’s use during pregnancy as there are hardly any clinical scenarios where the benefits appear to outweigh the risks.
Novartis has grown weary of waiting, dropping out of its deal to fund Mesoblast’s floundering COVID-19 treatment.
The lawsuit was filed by Public Health and Medical Professionals for Transparency, a nonprofit organization recently formed with a mission to obtain the data for the COVID-19 vaccines.
Despite the biggest vaccination drive in the U.S., the pandemic is still not over. The U.S. has reported more than 800,000 COVID-19 deaths, an increase of 500,000 since the vaccination started.
If successfully finalized, the transaction will give CSL access to Vifor’s pipeline of treatments for iron deficiency, kidney and cardio-renal diseases.